Inhibikase Therapeutics reported a net loss of $20.5 million in Q3 2026 but continues progress on its Phase 3 IMPROVE-PAH trial for IKT-001, a potential once-daily oral treatment for Pulmonary Arterial Hypertension (PAH). The trial has regulatory approval in 28 countries with 79 clinical sites activated. The company raised $50 million in July, boosting its cash to $193.3 million, supporting operations through key trial milestones. An interim safety readout is expected in early 2027, and the company is exploring combination therapies and additional PAH-related indications.
Inhibikase Therapeutics reported a net loss of $20.5 million in Q3 2026. For readers following the health sector, here is Pluang's market snapshot as of Nov 11, 2026 04:02 WIB: out of 150 priced US health stocks, 52 rose and 97 fell today. Notable movers include IONS at USD 28.10 with a 9.35% decline and Pluang order activity of 54% Buy, CRSP at USD 45.67 down 8.73% with 99% Sell orders, and TNGX up 8.18% to USD 24.60 with balanced buy/sell activity.
Cannabis Strategic Ventures has finalized its change of control with Scopien Technologies, an AI platform company, which now holds voting control through preferred stock. The company has appointed new leadership, including CEO Zameer Mulla, and plans...
Star Bulk Carriers Corp. has published its 2025 Environmental, Social and Governance (ESG) Report, its eighth annual report detailing the company's sustainability strategy, performance, and future objectives. The report, guided by the ESG Committee, ...
TELA Bio reported $19 million revenue in Q3 2026, down 8% year-over-year but with an 18% increase in international sales. The company reduced its operating loss by 21% sequentially and improved adjusted EBITDA loss by 55%, driven by a strategic cost ...
Auburn National Bancorporation, Inc. announced a quarterly cash dividend of $0.27 per share, payable on December 28, 2026, to shareholders recorded by December 10, 2026. The company is the parent of AuburnBank, an Alabama state-chartered bank with ab...
OpenTable's 2027 Quebec dining trends report shows a 9% increase in restaurant bookings, with 65% of Quebecers planning to dine out as much or more in 2027. Consumers prioritize value, local favorites, and meaningful experiences, often celebrating sm...
